He credits Wegovy with ending his desire for alcohol, saying he drank only now and then before quitting fully. One person's story, not a study.
Recap by typeshit. Video by @itsjakesjourney on TikTok.
Kalkine Media ties the attention on Lilly to orforglipron's progress, arguing a pill could scale cheaper than injectables and ease supply limits.
Smaller portions could become more common on shelves, with inflation and GLP-1 appetite changes both pushing food makers toward personal packs.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
Oral Wegovy brought in about $850 million in H1 2026 and holds over 80% of new US oral scripts. Lilly says Foundayo volume doubled in a month.
Pothier says social media and telehealth pulled GLP-1s partly out of doctors' hands, pushing Novo and Lilly to rethink launches. Novo CEO Mike Doustdar weighs in too.
Hill notes up to 40% of weight lost on these drugs isn't fat, but argues lean mass on a scan and actual muscle are not the same thing.
Loading…